VAXCYTE, INC. Operating Cash Flow
VAXCYTE, INC. (PCVX) reported Operating Cash Flow of -$513.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-05
- VAXCYTE, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$232.47M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$280.63M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$224.83M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$143.31M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$655.58M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$452.63M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$296.79M.
- VAXCYTE, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$170.60M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$232.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$513.10M 10-Q · filed 2026-08-05 | -$737.93M derived: sum of 3 quarters · filed 2026-08-05 | -$881.23M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$280.63M 10-Q · filed 2026-05-06 | -$505.46M derived: sum of 2 quarters · filed 2026-05-06 | -$648.76M derived: sum of 3 quarters · filed 2026-05-06 | -$769.93M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$224.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$368.14M derived: sum of 2 quarters · filed 2026-02-24 | -$489.30M derived: sum of 3 quarters · filed 2026-08-05 | -$655.58M 10-K · filed 2026-02-24 |
| 2025-09-30 | -$143.31M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$264.47M derived: sum of 2 quarters · filed 2026-08-05 | -$430.75M 10-Q · filed 2025-11-04 | -$542.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$121.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$287.44M 10-Q · filed 2026-08-05 | -$398.84M derived: sum of 3 quarters · filed 2026-08-05 | -$459.55M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$166.27M 10-Q · filed 2026-05-06 | -$277.68M derived: sum of 2 quarters · filed 2026-05-06 | -$338.38M derived: sum of 3 quarters · filed 2026-05-06 | -$459.78M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$111.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$172.11M derived: sum of 2 quarters · filed 2026-02-24 | -$293.50M derived: sum of 3 quarters · filed 2026-02-24 | -$452.63M 10-K · filed 2026-02-24 |
| 2024-09-30 | -$60.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$182.10M derived: sum of 2 quarters · filed 2025-11-04 | -$341.23M 10-Q · filed 2025-11-04 | -$470.04M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-06-30 | -$121.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$280.52M 10-Q · filed 2025-08-06 | -$409.33M derived: sum of 3 quarters · filed 2026-02-24 | -$466.88M derived: sum of 4 quarters · filed 2026-02-24 |
| 2024-03-31 | -$159.12M 10-Q · filed 2025-05-07 | -$287.93M derived: sum of 2 quarters · filed 2026-02-24 | -$345.48M derived: sum of 3 quarters · filed 2026-02-24 | -$408.22M derived: sum of 4 quarters · filed 2026-02-24 |
| 2023-12-31 | -$128.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | -$186.36M derived: sum of 2 quarters · filed 2026-02-24 | -$249.10M derived: sum of 3 quarters · filed 2026-02-24 | -$296.79M 10-K · filed 2026-02-24 |
| 2023-09-30 | -$57.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | -$120.29M derived: sum of 2 quarters · filed 2024-11-05 | -$167.98M 10-Q · filed 2024-11-05 | -$233.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | -$62.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$110.43M 10-Q · filed 2024-08-06 | -$175.65M derived: sum of 3 quarters · filed 2025-02-25 | -$214.20M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | -$47.69M 10-Q · filed 2024-05-08 | -$112.91M derived: sum of 2 quarters · filed 2025-02-25 | -$151.46M derived: sum of 3 quarters · filed 2025-02-25 | -$190.59M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | -$65.22M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | -$103.77M derived: sum of 2 quarters · filed 2025-02-25 | -$142.90M derived: sum of 3 quarters · filed 2025-02-25 | -$170.60M 10-K · filed 2025-02-25 |
| 2022-09-30 | -$38.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$77.67M derived: sum of 2 quarters · filed 2023-11-06 | -$105.38M 10-Q · filed 2023-11-06 | -$156.47M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$39.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | -$66.83M 10-Q · filed 2023-08-08 | -$117.92M derived: sum of 3 quarters · filed 2024-02-27 | -$146.34M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$27.70M 10-Q · filed 2023-05-08 | -$78.80M derived: sum of 2 quarters · filed 2024-02-27 | -$107.21M derived: sum of 3 quarters · filed 2024-02-27 | -$135.89M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$51.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$79.51M derived: sum of 2 quarters · filed 2024-02-27 | -$108.19M derived: sum of 3 quarters · filed 2024-02-27 | -$121.39M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$28.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$57.09M derived: sum of 2 quarters · filed 2022-11-07 | -$70.30M 10-Q · filed 2022-11-07 | -$81.07M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | -$28.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$41.88M 10-Q · filed 2022-08-08 | -$52.65M derived: sum of 3 quarters · filed 2023-02-27 | -$65.71M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | -$13.21M 10-Q · filed 2022-05-09 | -$23.97M derived: sum of 2 quarters · filed 2023-02-27 | -$37.03M derived: sum of 3 quarters · filed 2023-02-27 | -$46.20M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | -$10.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | -$23.82M derived: sum of 2 quarters · filed 2023-02-27 | -$32.99M derived: sum of 3 quarters · filed 2023-02-27 | -$46.63M 10-K · filed 2023-02-27 |
| 2020-09-30 | -$13.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | -$22.23M derived: sum of 2 quarters · filed 2021-11-10 | -$35.86M 10-Q · filed 2021-11-10 | -$50.27M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$9.17M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$22.80M 10-Q · filed 2021-08-11 | -$37.21M derived: sum of 3 quarters · filed 2022-02-28 | -$46.67M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$13.63M 10-Q · filed 2021-05-11 | -$28.04M derived: sum of 2 quarters · filed 2022-02-28 | -$37.50M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2019-12-31 | -$14.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | -$23.86M derived: sum of 2 quarters · filed 2022-02-28 | -$47.15M 10-K · filed 2022-02-28 | |
| 2019-09-30 | -$9.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$32.74M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | -$23.28M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | -$30.47M 10-K · filed 2021-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |